Mohamed Ahmed Zaki, Hamouda Abdel Khalek El-Bahnasy
{"title":"非维生素k拮抗剂口服抗凝治疗非瓣膜性房颤的经颅多普勒超声评价","authors":"Mohamed Ahmed Zaki, Hamouda Abdel Khalek El-Bahnasy","doi":"10.11648/j.cnn.20230701.13","DOIUrl":null,"url":null,"abstract":": Background : Warfarin with optimized international normalization ratio (INR); is significantly affect the Micro embolic signals (MES), in many studies. Non vitamin k antagonist oral anticoagulants (NOACs) are recently approved for stroke prevention in non valvular AF. In contrast to Warfarin; effect of NOACs on MES is not yet fully researched. Aim : To determine the effect of NOACs on MES, in comparison to warfarin in non valvular AF, to reflect the potential embolization risk. Methods : The incidence and number of MES was studied in patients with non valvular AF. Two groups in the current study; the first, patients were put on warfarin with INR levels were optimized to (2-3), and considered as a control group. The second; patients were put on NOAC (rivaroxaban, 15 mg /day). Study patients were recruited from cardiology outpatient clinics and departments (Al-Azhar University hospitals; Cairo and New Damietta, Egypt). Patients of the both groups were subjected to MES detection and counting by transcranial Doppler ultrasonography (TCD) monitoring. Results : MES did not detected in 22.5% in study groups; no statistically significant differences between study groups. The incidence and number of MES; within the warfarin group; MES were detected in (30 patients, 75%), while within the rivaroxaban group (32 patients, 80%). The average number of MES; in group one were (11.65 ±7.20), and in group two (11.50 ±7.20), with no significant statistical difference also. Conclusion : The effect of warfarin and NOAC use is not statistically different and Rivaroxaban is not inferior to warfarin.","PeriodicalId":93199,"journal":{"name":"Journal of clinical neurology and neuroscience","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Non Vitamin k Antagonist Oral Anticoagulation Assessment in Non Valvular Atrial Fibrillation Using Transcranial Doppler Ultrasonography\",\"authors\":\"Mohamed Ahmed Zaki, Hamouda Abdel Khalek El-Bahnasy\",\"doi\":\"10.11648/j.cnn.20230701.13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": Background : Warfarin with optimized international normalization ratio (INR); is significantly affect the Micro embolic signals (MES), in many studies. Non vitamin k antagonist oral anticoagulants (NOACs) are recently approved for stroke prevention in non valvular AF. In contrast to Warfarin; effect of NOACs on MES is not yet fully researched. Aim : To determine the effect of NOACs on MES, in comparison to warfarin in non valvular AF, to reflect the potential embolization risk. Methods : The incidence and number of MES was studied in patients with non valvular AF. Two groups in the current study; the first, patients were put on warfarin with INR levels were optimized to (2-3), and considered as a control group. The second; patients were put on NOAC (rivaroxaban, 15 mg /day). Study patients were recruited from cardiology outpatient clinics and departments (Al-Azhar University hospitals; Cairo and New Damietta, Egypt). Patients of the both groups were subjected to MES detection and counting by transcranial Doppler ultrasonography (TCD) monitoring. Results : MES did not detected in 22.5% in study groups; no statistically significant differences between study groups. The incidence and number of MES; within the warfarin group; MES were detected in (30 patients, 75%), while within the rivaroxaban group (32 patients, 80%). The average number of MES; in group one were (11.65 ±7.20), and in group two (11.50 ±7.20), with no significant statistical difference also. Conclusion : The effect of warfarin and NOAC use is not statistically different and Rivaroxaban is not inferior to warfarin.\",\"PeriodicalId\":93199,\"journal\":{\"name\":\"Journal of clinical neurology and neuroscience\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical neurology and neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11648/j.cnn.20230701.13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical neurology and neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/j.cnn.20230701.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Non Vitamin k Antagonist Oral Anticoagulation Assessment in Non Valvular Atrial Fibrillation Using Transcranial Doppler Ultrasonography
: Background : Warfarin with optimized international normalization ratio (INR); is significantly affect the Micro embolic signals (MES), in many studies. Non vitamin k antagonist oral anticoagulants (NOACs) are recently approved for stroke prevention in non valvular AF. In contrast to Warfarin; effect of NOACs on MES is not yet fully researched. Aim : To determine the effect of NOACs on MES, in comparison to warfarin in non valvular AF, to reflect the potential embolization risk. Methods : The incidence and number of MES was studied in patients with non valvular AF. Two groups in the current study; the first, patients were put on warfarin with INR levels were optimized to (2-3), and considered as a control group. The second; patients were put on NOAC (rivaroxaban, 15 mg /day). Study patients were recruited from cardiology outpatient clinics and departments (Al-Azhar University hospitals; Cairo and New Damietta, Egypt). Patients of the both groups were subjected to MES detection and counting by transcranial Doppler ultrasonography (TCD) monitoring. Results : MES did not detected in 22.5% in study groups; no statistically significant differences between study groups. The incidence and number of MES; within the warfarin group; MES were detected in (30 patients, 75%), while within the rivaroxaban group (32 patients, 80%). The average number of MES; in group one were (11.65 ±7.20), and in group two (11.50 ±7.20), with no significant statistical difference also. Conclusion : The effect of warfarin and NOAC use is not statistically different and Rivaroxaban is not inferior to warfarin.